Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43862   clinical trials with a EudraCT protocol, of which   7285   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000904-39
    Sponsor's Protocol Code Number:MK-4482-013
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-06-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-000904-39
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19.
    Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de MK-4482 en la prevención de la COVID-19 (infección por SARS-CoV-2, confirmada por el laboratorio, con síntomas) en adultos que conviven con una persona con COVID-19.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    MK4482-013 Phase 3 Study for Prevention of COVID-19 in Adults
    Estudio de fase 3 de MK-4482-013 para la prevención de la COVID-19 en adultos
    A.3.2Name or abbreviated title of the trial where available
    MK-4482 Phase 3 Study for Prevention of COVID-19 in Adults
    Estudio de fase 3 de MK-4482 para la prevención de la COVID-19 en adultos
    A.4.1Sponsor's protocol code numberMK-4482-013
    A.5.4Other Identifiers
    Name:INDNumber:155588
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck Sharp & Dohme de España SA
    B.5.2Functional name of contact pointInvestigación clínica
    B.5.3 Address:
    B.5.3.1Street AddressCalle Josefa valcárcel, 38
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28027
    B.5.3.4CountrySpain
    B.5.4Telephone number+34+91321 06 00
    B.5.5Fax number+3491321 05 90
    B.5.6E-mailensayos_clinicos@merck.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMolnupiravir
    D.3.2Product code MK-4482
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMolnupiravir
    D.3.9.1CAS number 2349386-89-4
    D.3.9.2Current sponsor codeMK-4482
    D.3.9.3Other descriptive name[(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2- yl]methyl 2-methylpropanoate
    D.3.9.4EV Substance CodeSUB208141
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Prophylaxis of COVID-19
    Profilaxis de la COVID-19 en adultos
    E.1.1.1Medical condition in easily understood language
    Prevention of COVID-19
    Prevención de la COVID-19
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level LLT
    E.1.2Classification code 10084382
    E.1.2Term Coronavirus disease 2019
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. To evaluate the efficacy of molnupiravir (MOV) compared with placebo for the prevention of laboratory-confirmed COVID-19 through Day 14 in participants who do not have confirmed or suspected COVID-19 at the time of screening and randomization and are residing with an individual with COVID-19.
    2. To evaluate the safety and tolerability of MOV compared with placebo.
    1.Evaluar la eficacia de molnupiravir (MOV) en comparación con placebo en la prevención de la COVID-19 confirmada por el laboratorio hasta el día 14 en participantes que no tengan COVID-19 confirmada ni presunta en el momento de la selección y la aleatorización y que convivan con una persona con COVID-19.
    2.Evaluar la seguridad y la tolerabilidad de MOV en comparación con un placebo
    E.2.2Secondary objectives of the trial
    1. To evaluate the efficacy of MOV compared with placebo for the prevention of laboratory-confirmed COVID-19 through Day 29 in participants who do not have confirmed or suspected COVID-19 at the time of screening and randomization and are residing with an individual with COVID-19.
    2. To evaluate the efficacy of MOV compared with placebo for the prevention of laboratory-confirmed COVID-19 through Day 14 in participants with undetectable SARS-CoV-2 in baseline nasopharyngeal (NP) swabs.
    3. To evaluate prevention of viral transmission through Day 14 for MOV compared with placebo in participants with undetectable SARS-CoV-2 in baseline NP swabs.
    1.Evaluar la eficacia de MOV en comparación con placebo en la prevención de la COVID-19 confirmada por el laboratorio hasta el día 29 en participantes que no tengan COVID-19 confirmada ni presunta en el momento de la selección y la aleatorización y que convivan con una persona con COVID-19.
    2.Evaluar la eficacia de MOV en comparación con placebo en la prevención de la COVID-19 confirmada por el laboratorio hasta el día 14 en participantes con SARS-CoV-2 indetectable en frotis nasofaríngeos (NF) basales.
    3.Evaluar la prevención de la transmisión vírica hasta el día 14 con MOV en comparación con placebo en participantes con SARS-CoV-2 indetectable en frotis NF basales.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. The participant is a household contact of an index case. The index case is a person with documented COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms case) and must have:
    a) A first positive SARS-CoV-2 test result from a sample collected within 72 hours prior to randomization of the participant(s), AND
    b) At least 1 of the following symptoms attributable to COVID-19: fever ≥38.0ºC, chills, cough, sore throat, shortness of breath or difficulty breathing with exertion, fatigue, nasal congestion, runny nose, headache, muscle or body aches, nausea, vomiting, diarrhea, loss of taste, or loss of smell, with symptom onset no earlier than 5 days prior to randomization of the participant(s).
    2. The participant does not have confirmed or suspected COVID-19.
    3. The participant is willing and able to take oral medication.
    4. The participant is male or female ≥18 years of age, at the time of providing documented informed consent.
    5. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 4 days after the last dose of study intervention:
    •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
    •Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below:
    - Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.
    - Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
    •Is not a WOCBP OR
    •Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 4 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention.
    - A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.
    - The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    - Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    - If contraceptives are interrupted in case of standard of care management of COVID-19 and resumed at a later time point, then abstinence must be practiced for the defined period of back-up contraception per the contraceptive product labeling. After this period, contraceptive use must adhere to protocol.
    7. The participant’s index case (or legally acceptable representative of the index case) has provided documented informed consent/assent for the collection of COVID-19 documentation requirements.
    8. The participant (or legally acceptable representative) has provided documented informed consent to participate in the study. The participant may also provide consent for participation in FBR but may participate in the study without participating in FBR.
    1. El participante es un contacto doméstico de un caso de referencia. Se entiende por caso de referencia una persona con COVID-19 documentada (caso de infección por el SARS-CoV-2, confirmada por el laboratorio, con síntomas) que debe tener:
    a) Un primer resultado positivo de la prueba de SARS-CoV-2 a partir de una muestra obtenida en las 72 horas previas a la aleatorización del participante Y
    b) Al menos uno de los síntomas siguientes atribuibles a la COVID-19: fiebre ≥38,0 ºC, escalofríos, tos, dolor de garganta, disnea o dificultad respiratoria con el esfuerzo, cansancio, congestión nasal, rinorrea, cefalea, dolores musculares o corporales, náuseas, vómitos, diarrea, pérdida del gusto o del olfato, con comienzo de los síntomas no más de 5 días antes de la aleatorización del participante(s).
    2. El participante no tiene COVID-19 confirmada ni presunta.
    3. El participante está dispuesto y es capaz de tomar medicación oral.
    4. Participante de cualquier sexo con una edad ≥18 años en el momento de otorgar su consentimiento informado documentado.
    5.En el estudio podrán participar varones que se comprometan a todo lo siguiente durante el período de intervención y hasta, como mínimo, cuatro días después de recibir la última dosis de la intervención del estudio:
    ● Abstenerse de mantener relaciones heterosexuales, como modo de vida habitual y preferido (abstinencia a largo plazo y persistente), y compromiso de mantener dicha abstinencia.
    O
    ● Comprometerse a utilizar métodos anticonceptivos, a menos que se confirme la presencia de azoospermia (por vasectomía o secundaria a una causa médica), tal como se detalla a continuación:
    - Comprometerse a utilizar preservativo masculino más uso por parte de la pareja de un método anticonceptivo adicional cuando mantengan relaciones sexuales con penetración vaginal con mujeres en edad fértil que no estén embarazadas.
    - El uso de anticonceptivos por los varones deberá cumplir la normativa local sobre métodos anticonceptivos para participantes en estudios clínicos.
    6.En el estudio podrán participar mujeres que no estén embarazadas ni en período de lactancia y que cumplan al menos una de las condiciones siguientes:
    ● No es una mujer en edad fértil. O
    ● Es una mujer en edad fértil y utiliza un método anticonceptivo muy eficaz (con un índice de fallos <1% anual), con escasa dependencia de la usuaria, o practica la abstinencia de relaciones heterosexuales como modo de vida preferido y habitual (abstinencia a largo plazo y persistente), durante el período de intervención y hasta, como mínimo, cuatro días después de recibir la última dosis de la intervención del estudio. El investigador deberá evaluar la posibilidad de fracaso del método anticonceptivo (es decir, incumplimiento o inicio reciente) en relación con la primera dosis de la intervención del estudio.
    - Las mujeres en edad fértil deberán dar negativo en una prueba de embarazo de alta sensibilidad (en orina o suero, según exija la normativa local) realizada en las 24 horas previas a la primera dosis de la intervención del estudio.
    -El investigador es responsable de revisar los antecedentes médicos, los antecedentes menstruales y la actividad sexual reciente para reducir el riesgo de incluir a una mujer con un embarazo de poco tiempo no detectado.
    - El uso de anticonceptivos por las mujeres deberá cumplir la normativa local sobre métodos anticonceptivos para participantes en estudios clínicos.
    - En caso de que se interrumpa el uso de anticonceptivos como parte de la asistencia habitual de la COVID-19 y se reanude en un momento posterior, deberá practicarse abstinencia sexual durante el período definido de anticoncepción de reserva conforme a la ficha técnica del anticonceptivo. Transcurrido dicho período, el uso de anticonceptivos deberá ajustarse al Protocolo.
    7.El caso de referencia del participante (o su representante legal) ha otorgado su consentimiento/asentimiento informado documentado para la recopilación de los requisitos de documentación relacionados con la COVID-19.
    8.El participante (o su representante legal) ha otorgado su consentimiento informado documentado para participar en el estudio. El participante también podrá otorgar su consentimiento para participar en las investigaciones biomédicas futuras, pero podrá participar en el estudio sin necesidad de hacerlo en dichas investigaciones.
    E.4Principal exclusion criteria
    1. The participant has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms).
    2. The participant is on dialysis or has reduced eGFR <30 mL/min/1.73 m2 (by the MDRD equation).
    3. The participant has either of the following conditions:
    •HIV with a recent viral load >50 copies/mL (regardless of CD4 count) or an AIDS defining illness in the past 6 months
    •A neutrophilic granulocyte absolute count <500/mm3
    4. The participant has a history of HBV or HCV infection with any of the following:
    •Cirrhosis
    •End-stage liver disease
    •Hepatocellular carcinoma
    •AST and/or ALT >3X upper limit of normal at screening
    5. The participant has a platelet count <100,000/μL or received a platelet transfusion in the 5 days prior to randomization.
    6. The participant has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator.
    7. The participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents.
    8. The participant is taking or is anticipated to require any prohibited therapies as outlined in the protocol.
    9. The participant has received a COVID-19 vaccine with the first dose 7 days or more prior to randomization.
    10. The participant is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.
    11. The participant has more than 1 individual currently (assessed at the time of consent), or within the last month, living in the household with confirmed or suspected COVID-19.
    12. The participant is living in a household of more than 10 people.
    13. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
    1. Antecedentes de infección por el SARS-CoV-2 confirmada por el laboratorio (con o sin síntomas).
    2. En diálisis o presencia de una FGe reducida <30 mL/min/1,73 m2 (según la ecuación MDRD).
    3. Presencia de alguna de las circunstancias siguientes:
    • VIH con una carga vírica reciente >50 copias/mL (independientemente del recuento de CD4) o una enfermedad definitoria de SIDA en los últimos 6 meses.
    • Recuento absoluto de granulocitos neutrófilos <500/mm3.
    4. Antecedentes de infección por el VHB o VHC con cualquiera de las circunstancias siguientes:
    • Cirrosis.
    • Hepatopatía terminal.
    • Carcinoma hepatocelular.
    • AST y/o ALT >3 veces el límite superior de la normalidad en el período de selección.
    5. Recuento de plaquetas <100 000/μL o recepción de una transfusión de plaquetas en los 5 días previos a la aleatorización.
    6. Hipersensibilidad o cualquier otra contraindicación a cualquiera de los componentes de la intervención del estudio, según lo determinado por el investigador.
    7. Presencia de cualquier circunstancia o proceso por el que, en opinión del investigador, la participación no sería lo mejor para el candidato o podría impedir, limitar o dificultar las evaluaciones especificadas en el protocolo, entre otros, participantes con trastornos que podrían limitar la absorción digestiva del contenido de las cápsulas.
    8. El candidato está tomando o cabe prever que necesite alguno de los tratamientos prohibidos que se describen en el Protocolo.
    9. El candidato ha recibido una vacuna contra la COVID-19 y la primera dosis se ha administrado 7 días o más antes de la aleatorización.
    10. Falta de disposición a abstenerse de participar en otro ensayo clínico intervencionista hasta el día 29 con un compuesto o dispositivo experimental, incluidos tratamientos contra la COVID-19.
    11. El candidato convive actualmente (evaluado en el momento de obtener el consentimiento), o lo ha hecho en el último mes, con más de una persona con COVID-19 confirmada o presunta.
    12. El candidato vive en un hogar de más de 10 personas.
    13. El candidato o un familiar directo (por ejemplo, cónyuge, progenitor o tutor legal, hermano o hijo) forma parte del personal del centro de investigación o del promotor implicado directamente en este estudio.
    E.5 End points
    E.5.1Primary end point(s)
    1. Percentage of participants with COVID-19 (laboratory-confirmed severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection with symptoms) through Day 14
    2. Percentage of participants with ≥1 adverse event
    3. Percentage of participants discontinuing from study therapy due to AE
    1. Porcentaje de participantes con COVID-19 (síndrome respiratorio agudo grave confirmado por laboratorio con infección por coronavirus 2 [SARS-CoV-2] con síntomas) hasta el día 14
    2.Porcentaje de participantes con ≥1 acontecimiento adverso
    3.Porcentaje de participantes que abandonaron el tratamiento del estudio debido a un AA.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Up to Day 14
    2. Up to 29 days
    3. Up to 5 days
    1. Hasta el día 14
    2. Hasta 29 días
    3. Hasta 5 días
    E.5.2Secondary end point(s)
    1. Percentage of participants with COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 29
    2. Percentage of participants who have undetectable SARS-CoV-2 in baseline nasopharyngeal (NP) swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) on or before Day 14
    3. Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop detectable SARS-CoV-2 in NP swabs on or before Day 14
    1.Porcentaje de participantes con COVID-19 (infección con síntomas de SARS-CoV-2 confirmada por laboratorio) hasta el día 29
    2.Porcentaje de participantes que tienen SARS-CoV-2 indetectable en frotis nasofaríngeos (NF) iniciales y desarrollan COVID-19 (infección por SARS-CoV-2 confirmada por laboratorio con síntomas) el día 14 o antes
    3.Porcentaje de participantes que tienen SARS-CoV-2 indetectable en frotis NF de referencia y desarrollan SRAS-CoV-2 detectable en frotis NF el día 14 o antes.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Up to Day 29
    2. Up to Day 14
    3. Up to Day 14
    1. Hasta el día 29
    2. Hasta el día 14
    3. Hasta el día 14
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA29
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Colombia
    Guatemala
    Japan
    Mexico
    Peru
    Philippines
    Russian Federation
    South Africa
    Turkey
    Ukraine
    United States
    France
    Hungary
    Romania
    Spain
    Argentina
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 670
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 670
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 210
    F.4.2.2In the whole clinical trial 1340
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-08-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-08-10
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2022-11-16
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 10:52:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA